Dare Bioscience (NASDAQ:DARE) Stock Crosses Below 200 Day Moving Average – Time to Sell?

Dare Bioscience, Inc. (NASDAQ:DARE) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.10 and traded as low as $1.85. Dare Bioscience shares last traded at $1.95, with a volume of 78,714 shares traded.

Analysts Set New Price Targets

Several equities analysts have recently commented on DARE shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dare Bioscience in a research report on Wednesday. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Dare Bioscience in a report on Tuesday, December 2nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $10.00.

Dare Bioscience Stock Performance

The firm has a market cap of $27.87 million, a P/E ratio of -1.04 and a beta of 0.78. The business’s fifty day simple moving average is $1.96 and its 200-day simple moving average is $2.10. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.06.

Dare Bioscience (NASDAQ:DARE) last issued its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.05. The company had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.01 million. As a group, sell-side analysts expect that Dare Bioscience, Inc. will post -0.49 earnings per share for the current year.

Institutional Trading of Dare Bioscience

Institutional investors have recently made changes to their positions in the stock. Raymond James Financial Inc. boosted its holdings in Dare Bioscience by 810.6% in the 3rd quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after buying an additional 13,650 shares during the period. Virtu Financial LLC bought a new position in shares of Dare Bioscience in the third quarter worth about $37,000. Finally, AMH Equity Ltd grew its position in shares of Dare Bioscience by 17.8% during the second quarter. AMH Equity Ltd now owns 193,603 shares of the biotechnology company’s stock worth $463,000 after purchasing an additional 29,301 shares in the last quarter. Hedge funds and other institutional investors own 6.70% of the company’s stock.

About Dare Bioscience

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.